Pleurodesis for Pneumothorax: Chemical vs. Surgical

Pleurodesis is a procedure that deliberately fuses the two layers of membrane lining your lungs and chest wall, eliminating the space where air can collect during a pneumothorax (collapsed lung). It is the most effective way to prevent a pneumothorax from coming back, and guidelines generally recommend it after a second episode or after a first episode with certain high-risk features. The procedure can be done chemically, by instilling an irritant through a chest tube, or mechanically during surgery. Both routes aim for the same endpoint, but the details of how they get there, how much they hurt, and how well they work differ in ways that matter when you’re facing this decision.

When Pleurodesis Is Recommended

Not every pneumothorax calls for pleurodesis. A first-time collapse in an otherwise healthy person is usually managed with observation or a simple chest drain, because many people never have a second episode. The picture changes when the air leak persists beyond a few days, or when the pneumothorax keeps returning. European guidelines recommend discussing intervention when an air leak lasts longer than three to five days and offering definitive treatment promptly for recurrent episodes.¹

French intensive care guidelines go further, recommending pleurodesis after a second episode on either side of the chest, regardless of how the first episode was treated. They also identify situations where pleurodesis should be considered after a very first episode: when there is blood in the pleural space alongside the air, when both lungs collapse at the same time, when the air leak will not stop despite suction drainage, or when the patient works as a pilot or in an isolated setting where a recurrence could be dangerous. Pneumothorax during pregnancy is another first-episode indication, though surgery is typically deferred until after delivery.²

How Pleurodesis Works Inside the Chest

The pleural space is lined on both sides by a thin sheet of mesothelial cells. When a sclerosing agent is introduced, these cells are the primary responders. They release a cascade of inflammatory signals and growth factors that recruit immune cells, activate the clotting cascade, and ultimately drive fibroblasts to lay down collagen and scar tissue between the two pleural layers.³ Early laboratory work showed that mesothelial cells exposed to tetracycline release a substance that stimulates fibroblast growth in a dose-dependent manner, and this activity persists for at least 48 hours after the drug is removed.⁴

Researchers have found that the inflammatory response varies considerably from one sclerosing agent to another, and even from one patient’s mesothelial cells to the next. There is no single neat pattern: different agents provoke different intensities of reaction at different time points. One consistent finding, though, is an increase in production of a pro-inflammatory molecule called IL-1β, which appears to play a central role in keeping the inflammatory process going long enough for the pleural surfaces to stick together.⁵ The end result is the same regardless of which agent triggers it: the pleural space fills with fibrous adhesions, and the lung is held against the chest wall so it cannot collapse again.

Chemical Agents Used for Pleurodesis

Several substances can provoke the inflammatory response needed for pleurodesis. The choice depends on availability, the clinical situation, and how invasive a procedure the patient can tolerate.

Talc

Talc is the most widely studied sclerosant for pleural effusions and is also used in pneumothorax. It can be delivered as a dry powder blown into the chest during thoracoscopy (poudrage) or as a slurry mixed with saline and injected through a bedside chest tube. A large randomized trial of 330 patients with malignant pleural effusions found no meaningful difference between the two methods: failure rates were about 22% with poudrage and 24% with slurry at 90 days, and none of the 24 secondary outcomes differed either.⁶ Earlier studies reached the same conclusion, leading some authors to argue that slurry should be preferred simply because it requires fewer resources than taking a patient to the operating room.⁷ Animal work in a porcine model confirmed no difference in the density or distribution of adhesions between the two delivery routes.⁸

One important safety lesson with talc involves particle size. Small-particle talc preparations were linked to rare but serious respiratory distress syndrome (ARDS). After institutions switched to large-particle talc, complication rates dropped significantly and ARDS cases were eliminated entirely.⁹ If talc pleurodesis is on the table, large-particle (“graded”) talc is now the standard.

Tetracycline and Doxycycline

Tetracycline was one of the earliest chemical agents used for pleurodesis in spontaneous pneumothorax. A systematic review of eleven studies found that tetracycline consistently showed lower recurrence rates compared to drainage alone, though the evidence was mixed in statistical significance across individual trials. The strongest single trial reported roughly half the odds of recurrence with tetracycline.¹⁰ Intravenous tetracycline has become difficult to obtain in many countries, so doxycycline, a closely related antibiotic, has taken its place. A systematic review comparing agents for persistent air leaks after secondary spontaneous pneumothorax reported success rates of about 84% for both doxycycline and talc, with doxycycline sealing air leaks faster, often within 11 to 36 hours.¹¹

Autologous Blood Patch

Autologous blood patch pleurodesis, where a patient’s own blood is drawn from a vein and injected into the pleural space through the chest tube, has gained attention as a gentler option. The blood clots on the pleural surface and seals small air leaks mechanically before an inflammatory reaction reinforces the seal. In a head-to-head randomized trial against doxycycline for secondary spontaneous pneumothorax, blood patch pleurodesis achieved a success rate of about 95% versus 84% for doxycycline. Median time to air leak closure was 24 hours with blood versus 36 hours with doxycycline, and the blood patch caused dramatically less pain: only 15% of blood patch patients reported significant post-procedure pain compared with 73% in the doxycycline group.¹²

A meta-analysis found that blood patch pleurodesis significantly shortened the time to air leak cessation compared with conservative management, though it did not shorten the overall hospital stay or increase the risk of complications like infection or fever.¹³ Early instillation appears to be key: in patients with secondary spontaneous pneumothorax who are too frail for surgery or decline it, giving the blood patch early is more effective than waiting.¹⁴

Mechanical and Surgical Approaches

When pleurodesis is performed during surgery, surgeons typically use one of two techniques to roughen the pleural lining. Pleural abrasion involves scrubbing the inner surface of the chest wall with gauze or a scratch pad to create a raw, inflamed surface. Partial pleurectomy physically strips away a section of the parietal pleura, usually at the apex of the chest where blebs (small blisters on the lung surface) tend to form. Both are done through video-assisted thoracoscopic surgery (VATS) and often combined with resection of any visible blebs.

The question of which technique is better has produced somewhat conflicting evidence. One single-center study found that recurrence after pleural abrasion was significantly higher than after apical pleurectomy: roughly one in four abrasion patients relapsed versus about one in seventy after pleurectomy, and surgical technique was the only factor that predicted recurrence.¹⁵ A needlescopic VATS study reached a similar conclusion, with no recurrences in the pleurectomy group over an average follow-up of 31 months versus about 9% recurrence in the abrasion group.¹⁶

A systematic review and meta-analysis pooling data across multiple studies, however, found no statistically significant difference in recurrence between the two techniques, though abrasion did come with shorter operating times, less blood loss, slightly shorter chest tube duration, and a modest reduction in hospital stay.¹⁷ The likely explanation for the discrepancy is that individual studies can be dominated by a single institution’s technique, while the pooled analysis blends many surgeons’ results and washes out that variation. In practice, many surgeons choose based on their own experience and what the chest looks like once the camera is inside.

Chemical Versus Mechanical Pleurodesis

A meta-analysis directly comparing chemical and mechanical pleurodesis after bullectomy for primary spontaneous pneumothorax found that chemical pleurodesis had a recurrence rate of about 1% compared with 4% for mechanical pleurodesis, a threefold difference in odds.¹⁸ That said, a randomized trial comparing mechanical abrasion with minocycline (a tetracycline-family drug) found no significant difference, though the trial was small enough that a real difference could have been missed.¹⁹

The practical takeaway is that adding a chemical agent to surgical bullectomy appears to further lower recurrence risk, and many surgeons do exactly that: resect visible blebs, abrade or strip the pleura, and then dust or spray a chemical agent for good measure. When pleurodesis is done without surgery, through a bedside chest tube, the chemical route is the only option available.

Pain Management After Pleurodesis

Pleurodesis hurts. The pleural surfaces are richly innervated, and deliberately inflaming them causes significant chest pain that can last days. There has been concern that nonsteroidal anti-inflammatory drugs (NSAIDs) might undermine the pleurodesis by suppressing the very inflammation that makes it work. A study that examined this question in adults after VATS pleurodesis found that patients given NSAIDs used less narcotic medication and had fewer opioid-related side effects, without any increase in recurrence: about 4% recurred in the NSAID group versus 5% in the group that received only narcotics.²⁰

In children, a similar concern arose around ketorolac, a potent injectable NSAID commonly used in pediatric surgery. A study found no differences in hospital stay, residual pneumothorax at discharge, or recurrence between children who received ketorolac and those who did not.²¹ These findings are reassuring: NSAIDs appear to provide better pain control without sabotaging the pleurodesis, though most surgeons still use them cautiously and as part of a multimodal pain regimen rather than the sole analgesic.

Long-Term Effects on the Chest

Pleurodesis does not end when the chest tube comes out. Because the procedure creates permanent adhesions inside the chest, some patients experience lasting changes in how the chest wall feels. A study with a median follow-up of nearly six years after VATS for primary pneumothorax found that about 8% of patients developed chronic chest pain and 22% developed chronic altered sensation (paresthesia) on the operated side. Only a very small fraction, about half a percent, needed regular pain medication long-term. Both chronic pain and paresthesia were independently linked to partial pleurectomy or pleural abrasion, longer postoperative chest tube duration, and the use of larger-bore chest tubes.²²

This is worth knowing before the procedure, especially for young patients who may live with the results for decades. The altered sensation is not painful for most people; it is more of a numbness or tingling. But about one in five patients notice it, and it is a direct consequence of the inflammation and scarring that make pleurodesis effective in the first place.

Pleurodesis in Children

Spontaneous pneumothorax is less common in children than in young adults, but it does occur, and recurrence rates are high enough that pleurodesis is sometimes offered early. A large study of children with primary spontaneous pneumothorax found that pleurodesis cut the risk of recurrence by about 40% and reduced the need for further surgery by about 60%. In a multivariate analysis, pleurodesis was the only factor that significantly predicted lower recurrence and fewer repeat operations.²³

One unique consideration in pediatric pleurodesis is the growth of the chest wall. The adhesions are permanent, and some surgeons prefer less aggressive techniques in younger patients to preserve flexibility as the thorax continues to develop. The evidence is thin here, and practice varies considerably between centers.

Catamenial Pneumothorax and Endometriosis

Catamenial pneumothorax is a rare form that occurs in women of reproductive age, typically within 72 hours of menstruation. It is linked to thoracic endometriosis, where endometrial tissue implants on the diaphragm or pleural surfaces and creates tiny holes that allow air into the chest with each menstrual cycle. Standard pleurodesis alone has a high failure rate in these patients because the underlying hormonal driver keeps producing new lesions.

A retrospective study found that combining diaphragmatic surgery (to repair defects) with chemical pleurodesis and subsequent hormonal therapy was effective in preventing recurrence in patients with catamenial pneumothorax and diaphragmatic involvement.²⁴ The triple approach, addressing the mechanical defect, sealing the pleural space, and suppressing the hormonal cycle that drives the disease, reflects how different catamenial pneumothorax is from the garden-variety spontaneous collapse.

Pleurodesis and Future Lung Transplantation

A longstanding worry among transplant surgeons has been that prior pleurodesis would make future lung transplantation too dangerous, because dense adhesions from the scarred pleural space could lead to uncontrollable bleeding when the old lung is removed. This concern has been especially prominent for patients with cystic fibrosis, who are prone to pneumothorax and may eventually need a transplant.

A study of lung transplant outcomes in cystic fibrosis patients found that those with a history of pneumothorax, including patients who had undergone pleural procedures, did develop dense pleural adhesions. However, these adhesions did not significantly affect surgical outcomes. The study concluded that previous pleural procedures for pneumothorax should not be considered a contraindication to transplant candidacy.²⁵ This is an important finding because it means that patients with recurrent pneumothorax do not have to avoid pleurodesis out of fear that it will disqualify them from a transplant down the road.

Outpatient and Ambulatory Options

Pleurodesis has traditionally been an inpatient procedure, but the boundaries are shifting. Digital chest drainage systems, which use electronic sensors to continuously measure air leak, have been shown in randomized trials to shorten hospital stays after thoracic surgery compared with traditional water-seal drains.²⁶ These devices make it easier to identify when the air leak has stopped, removing some of the guesswork that keeps patients in the hospital waiting for a surgeon to assess their drain.

In select cases, patients with persistent air leaks who cannot tolerate surgery can go home with an indwelling pleural catheter attached to a portable one-way valve. A case report described a patient with lymphangioleiomyomatosis (a rare cystic lung disease) who was discharged one day after catheter insertion with an ambulatory pneumothorax device and later underwent autologous blood patch pleurodesis, with the air leak resolving at six weeks.²⁷ This kind of approach remains uncommon and is mostly reserved for patients with complex, treatment-resistant air leaks, but it hints at where the field is heading.

Cost and Readmissions

Pleurodesis decisions are not made in a vacuum; hospital resources, operating room availability, and the cost of extended admissions all factor in. A large nationwide analysis comparing surgical (VATS) and medical pleurodesis for spontaneous pneumothorax used propensity-matched groups of over ten thousand patients each. Total calendar-year costs were similar, roughly $55,000 for VATS versus $52,000 for medical pleurodesis, with no statistically significant difference. But the VATS group had a lower 90-day readmission rate, about 27% versus 30%.²⁸ The takeaway is that the upfront investment in a surgical approach may pay for itself by preventing repeat visits to the emergency department and additional admissions for recurrent pneumothorax.

These numbers reflect the U.S. healthcare system and its pricing quirks; the relative cost comparison in other countries will look different. The readmission finding is probably more universally applicable, since it reflects the lower recurrence rate associated with surgical pleurodesis rather than billing codes.